Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Neurogene Inc. - Common Stock
(NQ:
NGNE
)
32.78
+1.72 (+5.54%)
Streaming Delayed Price
Updated: 2:20 PM EST, Nov 4, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
95,630
Open
31.00
Bid (Size)
32.40 (100)
Ask (Size)
33.16 (200)
Prev. Close
31.06
Today's Range
30.99 - 33.06
52wk Range
6.875 - 74.49
Shares Outstanding
42,425,071
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Thursday's Intraday Session
October 09, 2025
Via
Benzinga
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
October 09, 2025
From
Neurogene Inc.
Via
Business Wire
Performance
YTD
+43.2%
+43.2%
1 Month
+42.0%
+42.0%
3 Month
+50.9%
+50.9%
6 Month
+116.9%
+116.9%
1 Year
-50.3%
-50.3%
More News
Read More
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
October 08, 2025
From
Neurogene Inc.
Via
Business Wire
4 Biotech Stocks Seeing Explosive Momentum Gains
October 07, 2025
Via
Benzinga
Topics
ETFs
Stocks
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025
From
Neurogene Inc.
Via
Business Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 05, 2025
From
Neurogene Inc.
Via
Business Wire
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals
September 04, 2025
Via
Benzinga
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
August 11, 2025
From
Neurogene Inc.
Via
Business Wire
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction
August 11, 2025
Via
Benzinga
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 08, 2025
From
Neurogene Inc.
Via
Business Wire
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
July 30, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
July 11, 2025
Via
Benzinga
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2025
From
Neurogene Inc.
Via
Business Wire
Which stocks are moving on Tuesday?
July 01, 2025
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
July 01, 2025
Via
Benzinga
Which stocks are experiencing notable movement on Tuesday?
July 01, 2025
Via
Chartmill
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome
June 30, 2025
From
Neurogene Inc.
Via
Business Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2025
From
Neurogene Inc.
Via
Business Wire
This Foot Locker Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday
May 16, 2025
Via
Benzinga
Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV
May 16, 2025
From
Neurogene Inc.
Via
Business Wire
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday
May 14, 2025
Via
Benzinga
Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
May 13, 2025
Via
Benzinga
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates
May 09, 2025
From
Neurogene Inc.
Via
Business Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 08, 2025
From
Neurogene Inc.
Via
Business Wire
Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting
April 28, 2025
From
Neurogene Inc.
Via
Business Wire
Frequently Asked Questions
Is Neurogene Inc. - Common Stock publicly traded?
Yes, Neurogene Inc. - Common Stock is publicly traded.
What exchange does Neurogene Inc. - Common Stock trade on?
Neurogene Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Neurogene Inc. - Common Stock?
The ticker symbol for Neurogene Inc. - Common Stock is NGNE on the Nasdaq Stock Market
What is the current price of Neurogene Inc. - Common Stock?
The current price of Neurogene Inc. - Common Stock is 32.78
When was Neurogene Inc. - Common Stock last traded?
The last trade of Neurogene Inc. - Common Stock was at 11/04/25 02:20 PM ET
What is the market capitalization of Neurogene Inc. - Common Stock?
The market capitalization of Neurogene Inc. - Common Stock is 1.39B
How many shares of Neurogene Inc. - Common Stock are outstanding?
Neurogene Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today